Association of IFN ‐γ +874 T/A Polymorphism With COVID ‐19 Susceptibility, Severity, and Inflammatory Response: A Case–Control Study From Southern Iran
Journal of Clinical Laboratory Analysis · 2026
DOI: 10.1002/jcla.70362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2026. Verfasst von Nasir Arefinia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bio Environmental Health Hazards Research Center, Jiroft University of Medical Sciences, Jiroft, Iran. Hauptthemen laut MEDLINE: Interferon-gamma, COVID-19, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Significant interpatient variability in Coronavirus Disease 2019 (COVID‐19) manifestations highlights the influence of host genetic factors on disease outcomes. This study examines its association with COVID‐19 susceptibility, severity, and inflammatory markers in an Iranian population.
Methods
A retrospective case–control analysis was performed on 210 COVID‐19 patients and 210 age‐ and sex‐matched control subjects to evaluate whether the Interferon‐gamma (IFN‐γ) gene polymorphism (+874 T/A) is associated with disease severity.
Results
Patients had more comorbidities (e.g., diabetes 26.2% vs. 14.3%; hypertension 29.5% vs. 16.7%) and pronounced paraclinical abnormalities, including elevated Neutrophil‐to‐Lymphocyte Ratio (NLR) (8.1 vs. 1.9), C‐reactive protein (CRP) (45.5 vs. 3.2 mg/L), and lymphopenia (1.1 vs. 2.1 × 10 3 /μL; all p < 0.001). The TA genotype and A allele increased disease susceptibility (Odds Ratio (OR) =2.05 (95% CI: 1.32–3.19), p = 0.002; OR = 1.58 (95% CI: 1.11–2.25), p = 0.01, respectively). The TA genotype independently predicted severe disease (aOR = 2.85, p = 0.001), and both the TA and AA genotypes were linked to higher IL‐6 levels ( p < 0.001). TT carriers had shorter hospitalizations ( p < 0.01). Combining TA/AA with NLR improved severity prediction (AUC = 0.82 (95% CI: 0.76–0.88)).
Conclusion
The IFN‐γ +874 TA genotype was independently associated with severe COVID‐19. The TA genotype appears to confer increased risk of severe disease, whereas the AA genotype may be linked to a milder clinical presentation despite elevated inflammatory markers. Integration of genetic and hematological parameters may enhance risk stratification; however, further validation in larger and diverse populations is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bio Environmental Health Hazards Research Center, Jiroft University of Medical Sciences, Jiroft, Iran.
- Infectious Disease Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.
- Department of Bacteriology & Virology, Shiraz University of Medical Sciences, Shiraz, Iran.
- Faculty of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran.
- Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran.
ORCID-Profile: Nasir Arefinia, Bahman Aghcheli, Emad Behboudi
Zitieren
APA
Arefinia, N., Aghcheli, B., Hashemi, S. M. A., Ghoreshi, Z. A., & Behboudi, E. (2026). Association of IFN ‐γ +874 T/A Polymorphism With COVID ‐19 Susceptibility, Severity, and Inflammatory Response: A Case–Control Study From Southern Iran. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.70362
Vancouver
Arefinia N, Aghcheli B, Hashemi SMA, Ghoreshi ZA, Behboudi E. Association of IFN ‐γ +874 T/A Polymorphism With COVID ‐19 Susceptibility, Severity, and Inflammatory Response: A Case–Control Study From Southern Iran. Journal of Clinical Laboratory Analysis. 2026. doi:10.1002/jcla.70362
BibTeX
@article{Arefinia2026,
author = {Arefinia, Nasir and Aghcheli, Bahman and Hashemi, Seyed Mohammad Ali and Ghoreshi, Zohreh-Al-Sadat and Behboudi, Emad},
title = {Association of IFN ‐γ +874 T/A Polymorphism With COVID ‐19 Susceptibility, Severity, and Inflammatory Response: A Case–Control Study From Southern Iran},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
doi = {10.1002/jcla.70362}
}
EUVIMED